Global Long-acting Recombinant Human Erythropoietin 麻豆原创 Research Report 2024

Publication ID:

PB508243491

Publication Date:

August 23, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Long-acting erythropoietin (EPO) drugs are a type of medication used to stimulate the production of red blood cells in the body. These drugs are primarily prescribed for individuals with certain medical conditions, such as anemia associated with chronic kidney disease or cancer treatment.
The global Long-acting Recombinant Human Erythropoietin market was valued at US$ 843 million in 2023 and is anticipated to reach US$ 1102.1 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
North American market for Long-acting Recombinant Human Erythropoietin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-acting Recombinant Human Erythropoietin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Long-acting Recombinant Human Erythropoietin include Amgen, Johnson & Johnson and Kyowa Kirin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-acting Recombinant Human Erythropoietin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting Recombinant Human Erythropoietin.
Report Scope
The Long-acting Recombinant Human Erythropoietin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Long-acting Recombinant Human Erythropoietin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-acting Recombinant Human Erythropoietin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Amgen
Johnson & Johnson
Kyowa Kirin
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Segment by Application
Anemia
Kidney Disorders
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Long-acting Recombinant Human Erythropoietin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Long-acting Recombinant Human Erythropoietin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Long-acting Recombinant Human Erythropoietin 麻豆原创 Overview
1.1 Product Overview and Scope of Long-acting Recombinant Human Erythropoietin
1.2 Long-acting Recombinant Human Erythropoietin Segment by Type
1.2.1 Global Long-acting Recombinant Human Erythropoietin 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Epoetin-alfa
1.2.3 Epoetin-beta
1.2.4 Darbepoetin-alfa
1.2.5 Others
1.3 Long-acting Recombinant Human Erythropoietin Segment by Application
1.3.1 Global Long-acting Recombinant Human Erythropoietin 麻豆原创 Value by Application: (2024-2030)
1.3.2 Anemia
1.3.3 Kidney Disorders
1.3.4 Others
1.4 Global Long-acting Recombinant Human Erythropoietin 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Long-acting Recombinant Human Erythropoietin Revenue 2019-2030
1.4.2 Global Long-acting Recombinant Human Erythropoietin Sales 2019-2030
1.4.3 Global Long-acting Recombinant Human Erythropoietin 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Long-acting Recombinant Human Erythropoietin 麻豆原创 Competition by Manufacturers
2.1 Global Long-acting Recombinant Human Erythropoietin Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Long-acting Recombinant Human Erythropoietin Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Long-acting Recombinant Human Erythropoietin Average Price by Manufacturers (2019-2024)
2.4 Global Long-acting Recombinant Human Erythropoietin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Long-acting Recombinant Human Erythropoietin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Long-acting Recombinant Human Erythropoietin, Product Type & Application
2.7 Long-acting Recombinant Human Erythropoietin 麻豆原创 Competitive Situation and Trends
2.7.1 Long-acting Recombinant Human Erythropoietin 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Long-acting Recombinant Human Erythropoietin Players 麻豆原创 Share by Revenue
2.7.3 Global Long-acting Recombinant Human Erythropoietin 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Long-acting Recombinant Human Erythropoietin Retrospective 麻豆原创 Scenario by Region
3.1 Global Long-acting Recombinant Human Erythropoietin 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Long-acting Recombinant Human Erythropoietin Global Long-acting Recombinant Human Erythropoietin Sales by Region: 2019-2030
3.2.1 Global Long-acting Recombinant Human Erythropoietin Sales by Region: 2019-2024
3.2.2 Global Long-acting Recombinant Human Erythropoietin Sales by Region: 2025-2030
3.3 Global Long-acting Recombinant Human Erythropoietin Global Long-acting Recombinant Human Erythropoietin Revenue by Region: 2019-2030
3.3.1 Global Long-acting Recombinant Human Erythropoietin Revenue by Region: 2019-2024
3.3.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Region: 2025-2030
3.4 North America Long-acting Recombinant Human Erythropoietin 麻豆原创 Facts & Figures by Country
3.4.1 North America Long-acting Recombinant Human Erythropoietin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Long-acting Recombinant Human Erythropoietin Sales by Country (2019-2030)
3.4.3 North America Long-acting Recombinant Human Erythropoietin Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Long-acting Recombinant Human Erythropoietin 麻豆原创 Facts & Figures by Country
3.5.1 Europe Long-acting Recombinant Human Erythropoietin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Long-acting Recombinant Human Erythropoietin Sales by Country (2019-2030)
3.5.3 Europe Long-acting Recombinant Human Erythropoietin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Long-acting Recombinant Human Erythropoietin 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Long-acting Recombinant Human Erythropoietin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Long-acting Recombinant Human Erythropoietin Sales by Country (2019-2030)
3.6.3 Asia Pacific Long-acting Recombinant Human Erythropoietin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Long-acting Recombinant Human Erythropoietin 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Long-acting Recombinant Human Erythropoietin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Long-acting Recombinant Human Erythropoietin Sales by Country (2019-2030)
3.7.3 Latin America Long-acting Recombinant Human Erythropoietin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Long-acting Recombinant Human Erythropoietin 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Long-acting Recombinant Human Erythropoietin 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Long-acting Recombinant Human Erythropoietin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Long-acting Recombinant Human Erythropoietin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Long-acting Recombinant Human Erythropoietin Sales by Type (2019-2030)
4.1.1 Global Long-acting Recombinant Human Erythropoietin Sales by Type (2019-2024)
4.1.2 Global Long-acting Recombinant Human Erythropoietin Sales by Type (2025-2030)
4.1.3 Global Long-acting Recombinant Human Erythropoietin Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Type (2019-2030)
4.2.1 Global Long-acting Recombinant Human Erythropoietin Revenue by Type (2019-2024)
4.2.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Type (2025-2030)
4.2.3 Global Long-acting Recombinant Human Erythropoietin Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Long-acting Recombinant Human Erythropoietin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Long-acting Recombinant Human Erythropoietin Sales by Application (2019-2030)
5.1.1 Global Long-acting Recombinant Human Erythropoietin Sales by Application (2019-2024)
5.1.2 Global Long-acting Recombinant Human Erythropoietin Sales by Application (2025-2030)
5.1.3 Global Long-acting Recombinant Human Erythropoietin Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Application (2019-2030)
5.2.1 Global Long-acting Recombinant Human Erythropoietin Revenue by Application (2019-2024)
5.2.2 Global Long-acting Recombinant Human Erythropoietin Revenue by Application (2025-2030)
5.2.3 Global Long-acting Recombinant Human Erythropoietin Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Long-acting Recombinant Human Erythropoietin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Long-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Long-acting Recombinant Human Erythropoietin Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Kyowa Kirin
6.3.1 Kyowa Kirin Corporation Information
6.3.2 Kyowa Kirin Description and Business Overview
6.3.3 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Product Portfolio
6.3.5 Kyowa Kirin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Long-acting Recombinant Human Erythropoietin Industry Chain Analysis
7.2 Long-acting Recombinant Human Erythropoietin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Long-acting Recombinant Human Erythropoietin Production Mode & Process
7.4 Long-acting Recombinant Human Erythropoietin Sales and 麻豆原创ing
7.4.1 Long-acting Recombinant Human Erythropoietin Sales Channels
7.4.2 Long-acting Recombinant Human Erythropoietin Distributors
7.5 Long-acting Recombinant Human Erythropoietin Customers
8 Long-acting Recombinant Human Erythropoietin 麻豆原创 Dynamics
8.1 Long-acting Recombinant Human Erythropoietin Industry Trends
8.2 Long-acting Recombinant Human Erythropoietin 麻豆原创 Drivers
8.3 Long-acting Recombinant Human Erythropoietin 麻豆原创 Challenges
8.4 Long-acting Recombinant Human Erythropoietin 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Amgen
Johnson & Johnson
Kyowa Kirin

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.